SB16 versus reference denosumab in postmenopausal women with osteoporosis: 18-month outcomes of a phase III randomized clinical trial.
Chung YS, Langdahl B, Plebanski R, Czerwinski E, Dokoupilova E, Supronik J, Rosa J, Mydlak A, Sapula R, Rowińska-Osuch A, Baek KH, Urboniene A, Mordaka R, Ahn S, Rho YH, Ban J, Eastell R.
Chung YS, et al.
Bone. 2024 Dec 12;192:117371. doi: 10.1016/j.bone.2024.117371. Online ahead of print.
Bone. 2024.
PMID: 39674388